Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | KYNU | Q16719 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.44 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.44 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.44 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.44 |
| ▸ | RARG | P13631 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.44 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18425051 | 0.87 | KYNU (0.57) | ALDH1A1KYNUTRPM8ALOX15 | |
| SCHEMBL15123091 | 0.87 | KYNU (0.57) | ALDH1A1KYNUTRPM8ALOX15 | |
| SCHEMBL15123090 | 0.87 | KYNU (0.57) | ALDH1A1KYNUTRPM8ALOX15 | |
| SCHEMBL24021073 | 0.86 | ALDH1A1 (0.49) | MAPTRAB9AALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL25840243 | 0.85 | ALDH1A1 (0.47) | MAPTRAB9AALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL23011534 | 0.85 | ALDH1A1 (0.47) | MAPTRAB9AALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL25840242 | 0.84 | ALDH1A1 (0.46) | MAPTRAB9AALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL23485564 | 0.84 | ALDH1A1 (0.46) | MAPTRAB9AALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL21657923 | 0.84 | SIRT2 (0.48) | ALDH1A1KMT2ACA2MEN1CA1 | |
| SCHEMBL18465773 | 0.83 | MAPT (0.50) | MAPTRAB9AALDH1A1MAPK1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11667673-B2 | Therapeutically active compounds and their methods of use | SERVIER PHARMACEUTICALS LLC (US) | 2023-06-06 | — | — | US | disclosed |
| US-11021515-B2 | Therapeutically active compounds and their methods of use | AGIOS PHARMACEUTICALS, INC. (US) | 2021-06-01 | — | — | US | disclosed |
| US-20210024575-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2021-01-28 | — | — | US | disclosed |
| US-20200339626-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2020-10-29 | — | — | US | disclosed |
| US-10717764-B2 | Therapeutically active compounds and their methods of use | AGIOS PHARMACEUTICALS, INC. (US) | 2020-07-21 | — | — | US | disclosed |
| US-10689414-B2 | Therapeutically active compounds and their methods of use | AGIOS PHARMACEUTICALS, INC. (US) | 2020-06-23 | — | — | US | disclosed |
| US-10640534-B2 | Therapeutically active compositions and their methods of use | AGIOS PHARMACEUTICALS, INC. (US) | 2020-05-05 | — | — | US | disclosed |
| US-20190315802-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2019-10-17 | — | — | US | disclosed |
| US-20190023737-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2019-01-24 | — | — | US | disclosed |
| US-20180194802-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2018-07-12 | — | — | US | disclosed |
| US-9850277-B2 | Therapeutically active compositions and their methods of use | AGIOS PHARMACEUTICALS, INC. (US) | 2017-12-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200339626-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | IDH1, IDH3B, IDH3A | MAPT 4108/4885RAB9A 1519/4885ALDH1A1 413/4885 |
| US-11021515-B2 | Therapeutically active compounds and their methods of use | IDH1, IDH3B, IDH3A | MAPT 4108/4885RAB9A 1519/4885ALDH1A1 413/4885 |
| US-10689414-B2 | Therapeutically active compounds and their methods of use | IDH1, IDH3B, IDH3A | MAPT 4108/4885RAB9A 1519/4885ALDH1A1 413/4885 |
| US-20210024575-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | IDH1, IDH3B, IDH3A | MAPT 4108/4885RAB9A 1519/4885ALDH1A1 413/4885 |
| US-11667673-B2 | Therapeutically active compounds and their methods of use | IDH1, IDH3B, IDH3A | MAPT 4108/4885RAB9A 1519/4885ALDH1A1 413/4885 |
| US-20180194802-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | IDH1, IDH3B, IDH3A | MAPT 2648/4885RAB9A 1470/4885ALDH1A1 646/4885 |
| US-10640534-B2 | Therapeutically active compositions and their methods of use | IDH1, IDH3B, IDH3A | MAPT 2648/4885RAB9A 1470/4885ALDH1A1 646/4885 |
| US-10717764-B2 | Therapeutically active compounds and their methods of use | IDH1, IDH3B, IDH3A | MAPT 4108/4885RAB9A 1519/4885ALDH1A1 413/4885 |
| US-20190023737-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | IDH1, IDH3B, IDH3A | MAPT 4108/4885RAB9A 1519/4885ALDH1A1 413/4885 |
| US-20190315802-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | IDH1, IDH3B, IDH3A | MAPT 4108/4885RAB9A 1519/4885ALDH1A1 413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.